期刊文献+

PTTG在脑膜瘤组织芯片中的表达及意义

Expression and clinical significance of PTTG in human meningioma tissue microarray
暂未订购
导出
摘要 目的:应用免疫组化技术,研究垂体瘤转化基因(PTTG)在脑膜瘤组织芯片中的表达,进一步探讨其在脑膜瘤恶变、侵袭中的作用。方法:收集手术切除的脑膜瘤蜡块标本84例,以17例正常人硬脑膜为对照,采用免疫组化组织芯片技术检测PTTG在不同病理级别和不同侵袭性脑膜瘤中的表达。结果:正常硬脑膜组织中未见PTTG的表达,84例脑膜瘤中PTTG的阳性表达率为86.90%。良性及非良性脑膜瘤和侵袭性及非侵袭性脑膜瘤组间的PTTG表达阳性率差异无统计学意义(P>0.05);但组间染色阳性系数≥4分的阳性表达率差异有统计学意义(P<0.05)。结论:PTTG在大多数的脑膜瘤中有表达,恶性、侵袭性脑膜瘤中表达显著,提示其在人脑膜瘤发生、恶变、侵袭中发挥关键作用。 Objective To study the expression of pituitary tumor transforming gene (PTTG) in human meningioma tissue microarray by immunohistochemistry teclmique and further determine the role of PTrG in metastasis and invasiveness of meningioma. Methods 84 eases of meningioma specimens were collected. Taking 17 cases of normal human dura mater as control, the expression of FTTG in different patho- logical grades and different invasive meningiomas was detected by mieroarray immunohistochemical technique. Results The positive rate of expression of PTI'G was 86.90% in 84 cases of human meningioma tissue, and 0 in 17 cases of normal dura mater. The difference of the positive rate of PTrG expression in benign and non - benign meningioma, invasive and non invasive meningiomas was of no statistical signif- icance ( P 〉 0.05 ). But the positive expression rate of staining positive index ≥4 was statistically significant ( P 〈 0.05 ). Conclusion PT- TG is expressed in most meningiomas. Significant expression in malignant and invasive meningiomas indicates the key role of PTTG in tumor formation ,malignant transformation and invasion of human meningiomes.
出处 《吉林医学》 CAS 2013年第35期7349-7350,共2页 Jilin Medical Journal
基金 2009年常熟市科技局资助性项目[项目编号:cs200926]
关键词 脑膜瘤 垂体瘤转化基因 免疫组化 组织芯片 Meningioma Pituitary tumor transforming gene (PTYG) Immunohistoehemistry Tissue mieroarray (TMA)
  • 相关文献

参考文献4

二级参考文献28

  • 1倪灿荣.组织芯片的制备及在免疫组织化学中的应用[J].第二军医大学学报,2004,25(10):1156-1157. 被引量:4
  • 2张恒柱,武永康,李耀华,夏之柏.米非司酮对人脑膜瘤治疗作用的实验研究[J].中华神经外科杂志,2005,21(1):51-54. 被引量:9
  • 3Mccutcheon IE.Flyvbjerg A,Hill H,et al.Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice.J Neurosurg,2001,94(3):487-492.
  • 4Roser F,Nakamura M,Bellinzona M,et al.The prognostic value of progesterone receptor status in meningiomas.J Clin Pathol,2004,57(10):1033-1037.
  • 5Kononen J,Bubendorf L,Kallioniemi A,et al.Tissue microarrys for high throughput molecular profiling of tumor,specimens.Nat Med,1998,4(7):844-847.
  • 6Hirota Y,Tachibanab O,Uchiyamaa N,et al.Gonadotropin-releasing hormone (GnRH) and its receptor in human meningiomas.Clinical Neurology and Neurosurgery,2009,111(2):127-133.
  • 7Miltar RP,Lu ZL.Gonadotropin-releasing hormone receptors.Endocr Re,2004,25(2):235-275.
  • 8Fukui S, Otani N, Nawashiro H, et al. Subcellular localization of basic fibroblast growth factor and fibroblast growth factor rec-eptor 1 in pituitary adenomas[J]. Brain Tumor Pathol, 2002,19(1):23-29.
  • 9Lewis S, Blevins M, Denise K,et al. Aggressive pituitary tumors[J]. Oncology, 1998,21(9):1307-1309.
  • 10Zhang X, Horwitz G, Heaney A, et al. Pituitary tumor transfor-ming gene(PTTG)expression in pituitary adenomas[J]. Clin En-docrinol Metab, 1999,13(4):761-767.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部